This article is more than 5 years old. Information may no longer be current.

VIDEO: Storgard discusses lesinurad therapy for patients with gout

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SAN FRANCISCO — Chris Storgard, MD, vice president of Clinical Research and Development at Ardea Biosciences, a member of the AstraZeneca group, discusses two clinical trials with lesinurad in combination with a xanthine oxidase inhibitor as a treatment for hyperuricemia in patients with gout.

Storgard shares the results from the CRYSTAL and CLEAR trials of patients who did not meet target serum uric acid level goals on xanthine oxidase inhibitors alone.